Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

[New drugs toxicities: A new fight].

Bay JO, L'Allemain G, Maillet D.

Bull Cancer. 2019 May;106(5):405-406. doi: 10.1016/j.bulcan.2019.04.002. French. No abstract available.

PMID:
31128772
2.

[New year, new resolutions? 2019: Some changes in continuity].

Bay JO, L'Allemain G; comité de rédaction du Bulletin du cancer.

Bull Cancer. 2019 Jan;106(1):2-3. doi: 10.1016/j.bulcan.2019.01.001. French. No abstract available.

PMID:
30709565
3.

[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].

Bay JO, André T, Caux C, Evrard S, Gonçalves A, L'Allemain G, Magné N, Orbach D, Penel N, Rodrigues M, Thariat J, Thiery-Vuillemin A, Wislez M; Comité de Rédaction du Bulletin du Cancer.

Bull Cancer. 2019 Jan;106(1):12-23. doi: 10.1016/j.bulcan.2018.12.005. Epub 2019 Jan 3. Review. French.

PMID:
30612698
4.

[Virus and cancer: Still hot topic].

L'Allemain G, Bay JO, Dutreix M, Vignot S.

Bull Cancer. 2018 Feb;105(2):133-134. doi: 10.1016/j.bulcan.2018.01.007. French. No abstract available.

PMID:
29477229
5.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
6.

[Back to the future].

Vignot S, L'Allemain G, Bay JO; Comité de Rédaction.

Bull Cancer. 2017 Sep;104(9):701-702. doi: 10.1016/j.bulcan.2017.08.001. French. No abstract available.

PMID:
28886774
7.

[Public health and political will: Convergence and divergence].

Vignot S, L'Allemain G, Bay JO; Comité de rédaction.

Bull Cancer. 2017 Jul - Aug;104(7-8):597-598. doi: 10.1016/j.bulcan.2017.06.007. French. No abstract available.

PMID:
28734318
8.

[Tributes].

Dutreix M, Marty M, Bay JO, L'Allemain G, Vignot S; comité éditorial du Bulletin du cancer.

Bull Cancer. 2017 Feb;104(2):109. doi: 10.1016/j.bulcan.2017.01.002. French. No abstract available.

PMID:
28167102
9.

[French guidelines and PubMed indexation].

Vignot S, L'Allemain G, Bay JO; Comité de rédaction.

Bull Cancer. 2016 Nov;103(11):899-900. doi: 10.1016/j.bulcan.2016.11.001. French. No abstract available.

PMID:
27912823
10.

[French or English speaking publications: "À la carte"].

Vignot S, L'Allemain G, Bay JO; Comité de Rédaction.

Bull Cancer. 2016 Sep;103(9):709-10. doi: 10.1016/j.bulcan.2016.08.001. Epub 2016 Aug 31. French. No abstract available.

PMID:
27591904
11.

[Some reflexions about information on the hedge of highspeed communication].

Bay JO, Vignot S, L'Allemain G; Comité de rédaction du Bulletin du cancer.

Bull Cancer. 2016 Jul-Aug;103(7-8):605-6. doi: 10.1016/j.bulcan.2016.07.003. French. No abstract available.

PMID:
27543270
12.

État de l'art.

Vignot S, Bay JO, L'Allemain G.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S1. doi: 10.1016/S0007-4551(16)30138-2. French. No abstract available.

PMID:
27494964
13.

[Expensive cancer drugs funding is undergoing turbulent times].

Bay JO, L'Allemain G, Vignot S.

Bull Cancer. 2016 Apr;103(4):313-4. doi: 10.1016/j.bulcan.2016.03.004. French. No abstract available.

PMID:
27102881
14.

[On wales and men...].

L'Allemain G, Bay JO, Vignot S; Comité de rédaction du Bulletin du Cancer.

Bull Cancer. 2016 Mar;103(3):219. doi: 10.1016/j.bulcan.2016.02.007. French. No abstract available.

PMID:
26970506
15.

[Succession and continuity].

Vignot S, Bay JO, L'Allemain G; pour le Comité de rédaction.

Bull Cancer. 2016 Feb;103(2):123-4. doi: 10.1016/j.bulcan.2016.01.012. French. No abstract available.

PMID:
26879147
16.

[A point on a new year].

Bay JO, L'Allemain G, Massard C, Vignot S; Comité de rédaction.

Bull Cancer. 2016 Jan;103(1):1-2. doi: 10.1016/j.bulcan.2016.01.006. French. No abstract available.

PMID:
26831268
17.

[Doubling time of progression-free survival by palbociclib in metastatic breast cancer].

L'Allemain G.

Bull Cancer. 2015 Apr;102(4):300. doi: 10.1016/j.bulcan.2015.02.011. French. No abstract available.

PMID:
26042255
18.

[2015, an evolution without revolution, a change within continuity].

Bay JO, L'Allemain G, Massard C, Vignot S; comité de rédaction du Bulletin du Cancer.

Bull Cancer. 2015 Jan;102(1):2-3. doi: 10.1016/j.bulcan.2014.12.009. Epub 2014 Dec 30. French. No abstract available.

PMID:
25660914
19.

[NSAID use reduces the risk of breast cancer recurrence in overweight and obese women].

L'Allemain G.

Bull Cancer. 2014 Nov;101(11):1000. French. No abstract available.

PMID:
25580500
20.

[Editorial].

L'Allemain G, Vignot S, Massard C, Bay JO.

Bull Cancer. 2014 Jan;101(1):3. doi: 10.1684/bdc.2013.1878. French. No abstract available.

PMID:
25813518
21.

[The year 2013: one hundred years of the publication of Bulletin du Cancer].

Bay JO, L'Allemain G.

Bull Cancer. 2013 Jan 1;100(1):3-4. French. No abstract available.

22.

[Chromotripsy].

L'Allemain G.

Bull Cancer. 2011 Mar;98(3):227-8. French. No abstract available.

23.

[Angiogenesis].

L'Allemain G, Soria JC.

Bull Cancer. 2007 Jul;94 Spec No:S159. French. No abstract available.

PMID:
17845999
24.

[48th World Congress of the American Society of Hematology].

L'Allemain G; l'American Society of Hematology.

Bull Cancer. 2007 May;94(5):489-94. French. No abstract available.

25.

[Cancer prevention: congress report].

L'Allemain G.

Bull Cancer. 2004 May;91(5):457-9. French. No abstract available.

26.

[Ovca1 gene, deleted in ovarian cancer is a special tumor suppressor].

L'Allemain G.

Bull Cancer. 2004 Apr;91(4):301-2. French. No abstract available.

PMID:
15242311
27.

[Absence of the Fos oncogene induces rhabdomyosarcoma in the p53(-/-) mouse].

L'Allemain G.

Bull Cancer. 2004 Feb;91(2):127-8. French. No abstract available.

28.

[HER-ErbB family of receptors and their ligands: mechanisms of activation, signals and deregulation in cancer].

L'Allemain G.

Bull Cancer. 2003 Nov;90 Spec No:S179-85. Review. French.

PMID:
14763137
29.

RKIP, un suppresseur des métastases osseuses du cancer de la prostate.

L'Allemain G.

Bull Cancer. 2003 Oct 1;90(10):819. French. No abstract available.

PMID:
14706910
Free Article
30.

[An original mechanism of action for TIMP2, a tissue-inhibitor of matrix metalloproteinases].

L'Allemain G.

Bull Cancer. 2003 Nov;90(11):935. French. No abstract available.

31.

[Ras signals up there where no one expects it].

L'Allemain G.

Bull Cancer. 2003 Aug-Sep;90(8-9):672-3. French. No abstract available.

32.

[Beware of magic pills].

L'Allemain G.

Bull Cancer. 2002 Oct;89(10):835-6. French. No abstract available.

33.

[Report on 93rd AACR].

L'Allemain G.

Bull Cancer. 2002 Jul-Aug;89(7-8):729-32. French. No abstract available.

34.

[The hypoxia-inducible factor HIF as a new target in cancer research].

L'Allemain G.

Bull Cancer. 2002 Mar;89(3):257-60. Review. French.

35.

[Update on . . . the proteasome inhibitor PS341].

L'Allemain G.

Bull Cancer. 2002 Jan;89(1):29-30. Review. French.

36.

[New molecules for therapeutic targets in cancer].

L'Allemain G, Bénard J.

Bull Cancer. 2001 Dec;88(12):1240-5. French. No abstract available.

37.

[Involvement of ephrins and their receptors in oncogenesis].

L'Allemain G.

Bull Cancer. 2000 Jul;87(7-8):529-30. French.

38.

[Multiple actions of EGCG, the main component of green tea].

L'Allemain G.

Bull Cancer. 1999 Sep;86(9):721-4. French.

39.

MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells.

Rivard N, Boucher MJ, Asselin C, L'Allemain G.

Am J Physiol. 1999 Oct;277(4):C652-64. doi: 10.1152/ajpcell.1999.277.4.C652.

PMID:
10516095
40.

A role for nuclear factor kappaB in the antiapoptotic function of insulin.

Bertrand F, Atfi A, Cadoret A, L'Allemain G, Robin H, Lascols O, Capeau J, Cherqui G.

J Biol Chem. 1998 Jan 30;273(5):2931-8.

41.

Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts.

L'Allemain G, Lavoie JN, Rivard N, Baldin V, Pouyssegur J.

Oncogene. 1997 Apr 24;14(16):1981-90.

43.

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

Lavoie JN, L'Allemain G, Brunet A, Müller R, Pouysségur J.

J Biol Chem. 1996 Aug 23;271(34):20608-16.

44.

Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts.

Rivard N, L'Allemain G, Bartek J, Pouysségur J.

J Biol Chem. 1996 Aug 2;271(31):18337-41.

45.

A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry.

Lavoie JN, Rivard N, L'Allemain G, Pouysségur J.

Prog Cell Cycle Res. 1996;2:49-58. Review.

PMID:
9552382
46.

[MAP kinase module: role in the control of cell proliferation].

Brunet A, Brondello JM, L'Allemain G, Lenormand P, McKenzie F, Pagès G, Pouysségur J.

C R Seances Soc Biol Fil. 1995;189(1):43-57. Review. French.

PMID:
7648366
47.

Chemotactic peptides induce phosphorylation and activation of MEK-1 in human neutrophils.

Grinstein S, Butler JR, Furuya W, L'Allemain G, Downey GP.

J Biol Chem. 1994 Jul 29;269(30):19313-20.

48.

Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1).

Pagès G, Brunet A, L'Allemain G, Pouysségur J.

EMBO J. 1994 Jul 1;13(13):3003-10.

49.

Deciphering the MAP kinase pathway.

L'Allemain G.

Prog Growth Factor Res. 1994;5(3):291-334. Review.

PMID:
7888635
50.

Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.

Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouysségur J.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8319-23.

Supplemental Content

Loading ...
Support Center